Case Study: GLP-1 Medication Research Study
Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
Tekton met enrollment goals for a GLP-1 study in Moore, OK three months early, with a one-day regulatory turnaround.
Tekton delivered a Phase 2 migraine study in Yukon, OK with 100% patient retention and a 1.5-day regulatory turnaround.
Tekton reached 240% of enrollment goals, enrolling 12 patients in a CGM study for pregnant women with diabetes.
Tekton Research averaged a one-day turnaround from site activation to first patient visit across seven sites in a recent Phase 3 norovirus vaccine trial.
Tekton Research achieved an average of one day from site activation to first patient visit across seven sites in a Phase 3 norovirus vaccine trial.